Lutetium Lu 177 dotatate is under clinical development by POINT Biopharma Global and currently in Phase III for Neuroendocrine Tumors. According to GlobalData, Phase III drugs for Neuroendocrine Tumors have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lutetium Lu 177 dotatate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium Lu 177 dotatate overview
lutetium Lu 177 dotatate (PNT-2003) is under development for the treatment of Neuroendocrine tumors including both GEP-NETs and non-GEP-NETs. It consists of radioligand conjugated to lutetium 177. It is administered through intravenous route. The drug candidate is being developed based on canSEEK technology and acts by targeting somatostatin receptor 2 (SSTR2).
POINT Biopharma Global overview
Point Biopharma Global (Point Biopharma), formerly Therapeutics Acquisition Corp, is a radiopharmaceutical company. It develops and commercializes radioligands for cancer. The company is investigating PNT2002 against mCRPC (metastatic castration resistant prostate cancer); PNT2003 program to treat neuroendocrine tumors; PNT2004 targeting solid tumors expressing FAP (fibroblast activation protein); and PNT2001 against prostrate cancer. It utilizes CanSEEK platform technology to develop cancer treatments. The company’s technology aims to minimize toxicity caused by off-target delivery by activating radiopharmaceuticals that target ligands. Point Biopharma is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Lutetium Lu 177 dotatate’s drug-specific PTSR and LoA scores, buy the report here.